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1
Bacteria are key elements for human health. Two evidences support this notion, the 2 existence of a stably population of microbes, termed microbiota, in healthy individuals 3 and the number of health disorders associated to axenic (germ-free) animals [1, 2] . In 4 addition, bacteria have been actively administered in patients suffering from different 5 illnesses for over a century. These intentional administrations are in general carried out 6 with natural isolates obtained from the microbiota of healthy individuals and are 7 referred to as probiotics. In most cases they belong to lactic acid bacteria (LAB) and in 8 a lesser extent to Escherichia coli strains [3] . The development of efficient DNA 9 technologies for manipulation of microbial genomes and the increasing knowledge of 10 the molecular basis of diseases are allowing the engineering of tailored bacteria for the 11 treatment of human disorders. Bacteria can be altered to produce a continuous and 12 inexpensive supply of heterologous molecules of biomedical interest, such as human 13 hormones, interleukins (ILs) and antibodies (Abs) within specific organs or tissues. We 14 have restricted this review to bacterial engineering for human therapies, but similar 15 concepts can be applied for the development of live bacterial vaccines [4] . 16
17
Engineered bacteria against inflammatory and autoimmune disorders 18
Inflammatory bowel diseases (IBDs) have been prototypical targets of probiotic 19 therapies, given the immunomodulatory effects that certain strains are able to exert in 20 the gastrointestinal tract (GIT). Patients suffering from IBDs frequently have alterations 21 in pattern recognition receptors and pro-inflammatory genes, which elicit an abnormal 22 activation of the immune system in the gut and lead to chronic intestinal inflammation 23 and to an increased rate of oxidative stress [5] . Different bacteria, mostly LAB, have 24 been engineered to express a wide variety of compounds in situ (i.e. anti-inflammatory 25 cytokines, anti-oxidant enzymes) to prevent the appearance of these symptoms [6] . 26
These strategies are summarized in Figure 1 . At least three of these engineered 27 microorganisms have been tested in clinical trials. A Lactococcus lactis strain, 28 engineered to secrete the anti-inflammatory cytokine IL-10 [7] showed a clinical benefit 29 suggesting an antigen-specific immunosuppression. A similar combination therapy 1 based on anti-CD3 Abs and the oral delivery of engineered L. lactis secreting IL-10 and 2 the diabetes-related auto-antigen glutamic acid decarboxylase (GAD)-65 has been 3 reported [17] . This combination was effective in the treatment of advanced stages of 4 T1D with severe hyperglycemia. Induction of tolerance against heat shock proteins 5 (HSPs) has been also achieved using LAB. HSPs partipate in the control of 6 autoimmunity and in the cellular response to stress and are overexpressed in diseases 7 involving inflammation and autoimmunity mechanisms, such as atherosclerosis and 8 encephalomyelitis [18] . Oral administration of L. lactis strains secreting different forms 9 of HSP-65 exerted a protective effect against endothelial damage and against the 10 formation of atherosclerotic lesions in a low-density lipoprotein receptor-deficient 11 (LDL-RD) mouse model [19] . This approach also prevented the development of 12 encephalomyelitis in mice, showing reduced inflammatory cell infiltrate in the spinal 13 cord [20] . These effects were associated with increased production of IL-10 and reduced 14 levels of IL-17 and interferon gamma (IFN-). 15
16
Engineered bacteria against cancer 17
Firsts reports of bacterial treatments against solid tumors date from the end of the 19th 18 century. Over the years many genera of (facultative and strict) anaerobic bacteria (e.g. Bacteria can bypass problems associated with poor selectivity and limited tumor 4 penetrability of conventional cancer chemotherapies, and can be finely engineered to 5 sense and respond to the tumor microenvironment [28] . However, the antitumoral effect 6 of bacterial growth within tumors is generally weak, and different strategies have been 7
followed to improve their therapeutic potential against cancer. One of them is the direct 8 destruction of tumor cells through the secretion of bacterial toxins in situ (e.g. 9
Staphylococcus aureus alpha hemolysin) [29, 30] or the expression of pro-drug 10 converting enzymes that locally convert non-toxic prodrugs into drugs, like E. coli 11 cytosine deaminase (CD) that transforms non-toxic prodrug 5-Fluorocytosine into toxic 12 5-Fluorouracil, resulting in a bacterial-directed enzyme prodrug therapy (BDEPT) 13 localized in tumor areas [31] . BDEPT provides an excellent tumor selectivity since the 14 drug is produced in situ, however, and similarly to conventional chemotherapy, its 15 efficiency is highly dependent on physico-chemical properties of the prodrug that will 16 define its ability to reach deep areas of the tumor in which bacteria (and therefore the 17 converting enzyme) are located. In another strategy, engineered bacteria compete with 18 the mechanisms that foster tumor formation (i.e. angiogenesis, resistance to apoptosis, 19 evasion from the immune system, etc.) through the in situ delivery of polypeptides with 20 pro-apoptotic activity (e.g. TNF-related apoptosis-inducing ligand -TRAIL-, Fas ligand, 21 Noxa), anti-angiogenic factors (e.g. Endostatin, Thrombospondin 1), and cytokines (e.g. of the desired therapeutic protein can be specifically triggered within tumors using 28 bacterial promoters responding to quorum sensing molecules released by the high-29 density of bacteria in tumors [38] . A similar strategy has also been employed to amplify 1 the expression of the desired protein induced with small molecules (e.g. L-arabinose) 2 that diffuse poorly within the tumor mass [39] . Bacteria have also been engineered to 3 silence the expression of important genes related to tumor development through RNA 4 interference. For instance, E. coli was engineered to transfer to host cells plasmids 5 encoding short-hairpin RNAs (shRNAs) silencing beta-1, whose 6 overexpression is involved in several types of cancer [40] . This therapy has been 7 granted by the FDA as orphan drug for the treatment of familial adenomatous polyposis In addition, engineered bacteria must have own containment strategies resistant to 10 environmental supplementation, mutagenic drift and horizontal gene transfer. All these 11 safeguards should avoid the spreading of these microorganisms into the environment 12 and the proliferation of deleterious bacteria. Classically, biocontainment has been 13 achieved through either engineered auxotrophies (e.g. strains deficient for thymidylate 14 synthase) or induced lethality, which have been applied in clinical trials [8, 13] . 15
Synthetic biology is providing stricter biocontainment of the engineered bacteria. 16
Minimal genomes encoding only the genes needed to sustain life might preclude 17 unexpected evolution of engineered microbes. These minimal genomes could be 18 generated through genome reduction techniques [75] and provide an excellent genetic 19 chassis to implement the designed therapeutic gene devices (Fig. 4) . However, the 20 definitive firewall for biocontainment might be the use of artificial genetic languages. 21
Indeed, there are already available engineered E. coli strains that either incorporate a 22 non-standard amino-acid in the core of essential proteins [76] or the synthetic thymine 23 analogue 5-chlorouracil instead of the natural thymine nucleotide in the DNA [77] . 24
These strains exhibit strong resistance to evolutionary escape through mutagenesis or 25 horizontal gene transfer, and cannot be supplemented with natural compounds. 26
27
Concluding remarks 28
Engineered bacteria represent an effective method to deliver therapeutic molecules in 29 vivo allowing the development of novel treatments against infections and major human 1 diseases such as inflammatory, autoimmune and metabolic disorders, and cancer. In 2 addition, engineered bacteria could help to reprogram host cells by delivering 3 transcription factors and enzymes for genome modification. Next-generation therapeutic 4 applications of bacteria will be based on the conscious design of microorganisms with 5 defined properties for specific applications, rather than on the finding of probiotic 6
isolates. This fine engineering can complement a genetic bacterial chassis with modules 7 and parts designed de novo or based on the engineering of the plethora of devices that 8 bacteria have evolved to interact with human cells, such as immuno-modulatory and 9 effector proteins, chemotactic sensor systems, adhesins and protein delivery 10 machineries. Human origins are those of nomad hunters and fruit pickers that flourished 11 when they learned how to breed and cross wild animals and plants into the variants that 12 still feed ourselves today. Similarly, microbiology started from microbe hunters 13 studying wild bacteria and is now evolving to the rationale design of safe engineered 14 bacteria able to monitor our bodies and fight against human diseases.
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